Ubrogepant (Ubrelvy): Indication: For the acute treatment of migraine, with or without aura, in adults: Reimbursement Recommendation
Abstract
What is the reimbursement recommendation for ubrelvy?: Canada’s Drug Agency (CDA-AMC) recommends that Ubrelvy be reimbursed by public drug plans for the acute treatment of migraine, with or without aura, in adults if certain conditions are met.
Why did cda-amc recommend reimbursement?: The Canadian Drug Expert Committee (CDEC) determined that Ubrelvy demonstrates acceptable clinical value compared with appropriate comparators (triptans) in adult patients with migraine. This determination was enough for CDEC to recommend that Ubrelvy be reimbursed. Evidence from 2 clinical trials showed that patients who had a migraine attack and took Ubrelvy were more likely to be pain free or have less severe pain, and they were less likely to have symptoms associated with migraine, when compared with patients taking a placebo pill. Evidence from an indirect treatment comparison was associated with limitations and did not consistently demonstrate meaningful differences between Ubrelvy and publicly funded oral triptans that are commonly used to treat migraine attacks. While acknowledging the uncertainty of the indirect treatment comparison, CDEC found it reasonable to consider Ubrelvy and publicly funded oral triptans comparable.
Which patients are eligible for coverage?: Ubrelvy should only be covered for adults with migraine, with or without aura.
What are the conditions for reimbursement?: Ubrelvy should only be reimbursed if initiated in adults with a history of migraine attacks…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.